Teza Capital Management’s Vaxcyte PCVX Stock Holding History

Teza Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$242K	Buy	+4,248	New	+$248K	0.22%	210

Other funds holding PCVX

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Avior Wealth Management Omaha, Nebraska $3.79B AUM 15.36% 1-Year Est. Return

Values First Advisors Gray, Tennessee $213M AUM 20.51% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Teza Capital Management's PCVX Position: Q3 2026 in Review

Teza Capital Management opened a new position in Vaxcyte (PCVX) in Q3 2026: 4,248 shares worth $242K. The stake represents 0.22% of the portfolio and ranks #210 among its holdings.

42 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

Teza Capital Management held 4,248 shares of Vaxcyte worth $242K as of Q3 2026.
Vaxcyte was a new Teza Capital Management position in Q3 2026.
Vaxcyte made up 0.22% of Teza Capital Management's portfolio in Q3 2026, its #210 holding.
42 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Teza Capital Management's 13F filing for Q3 2026, filed 23 Oct 2026.